{"id":722,"date":"2026-09-01T15:21:54","date_gmt":"2026-09-01T15:21:54","guid":{"rendered":"https:\/\/nhdbio.com\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/"},"modified":"2026-09-01T15:32:23","modified_gmt":"2026-09-01T15:32:23","slug":"retatrutide-phase-2-obesity-trial-338-adults-48-weeks","status":"publish","type":"case_study","link":"https:\/\/nhdbio.com\/fr\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/","title":{"rendered":"Essai de phase Retatrutide sur l'ob\u00e9sit\u00e9 2\u00a0: adultes 338 sur des semaines 48"},"content":{"rendered":"<h2>Pourquoi cette \u00e9tude est fr\u00e9quemment cit\u00e9e<\/h2>\n<p>Retatrutide a \u00e9t\u00e9 con\u00e7u pour activer les r\u00e9cepteurs GIP, GLP-1 et le glucagon. L'article 2023 est le document central \u00e9valu\u00e9 par des pairs sur la d\u00e9termination des doses humaines pour le compos\u00e9 dans l'ob\u00e9sit\u00e9. Il est donc plus utile que les r\u00e9sum\u00e9s qui ne mentionnent que le pourcentage de changement le plus important sans les groupes de doses, les r\u00e9sultats du placebo ou les observations de s\u00e9curit\u00e9.<\/p>\n<h2>Comment le proc\u00e8s a \u00e9t\u00e9 structur\u00e9<\/h2>\n<p>Les adultes r\u00e9pondant aux crit\u00e8res BMI et \u00e0 l'\u00e9tat de sant\u00e9 li\u00e9s au poids ont \u00e9t\u00e9 randomis\u00e9s parmi six sch\u00e9mas th\u00e9rapeutiques de r\u00e9tatrutide et un placebo. Le ratio d'allocation et les diff\u00e9rents sch\u00e9mas de dose initiale faisaient partie de la conception, ce qui signifie que l'\u00e9tude \u00e9valuait la r\u00e9ponse \u00e0 la dose et la tol\u00e9rabilit\u00e9 ainsi que les signaux d'efficacit\u00e9. Le crit\u00e8re d'\u00e9valuation de la semaine 24 \u00e9tait principal\u00a0; la semaine 48 \u00e9tait secondaire.<\/p>\n<h2>Que signifient les chiffres<\/h2>\n<p>Le changement moyen signal\u00e9 le plus important s'est produit dans le groupe mg 12, mais la publication a \u00e9galement signal\u00e9 une r\u00e9ponse gradu\u00e9e dans les groupes mg 1, 4 et 8 et une comparaison avec un placebo. Les r\u00e9sultats seuils au cours de la semaine 48 variaient \u00e9galement selon le groupe. Il s'agit d'estimations d'essais au niveau de groupe, et non d'une pr\u00e9vision pour un individu et non d'une preuve qu'un produit vendu sous le m\u00eame nom de compos\u00e9 est interchangeable avec l'intervention de l'\u00e9tude.<\/p>\n<div class=\"pfm-case-callout\"><strong>Contr\u00f4le d'interpr\u00e9tation\u00a0:<\/strong> le chiffre \u221224.2%, souvent r\u00e9p\u00e9t\u00e9, est la moyenne des moindres carr\u00e9s pour un groupe randomis\u00e9 \u00e0 la semaine 48. Il ne s'agit pas du r\u00e9sultat obtenu pour chaque participant et il n'a pas \u00e9t\u00e9 g\u00e9n\u00e9r\u00e9 par un essai direct r\u00e9tatrutide versus tirz\u00e9patide.<\/div>\n<h2>Ce qui reste en suspens<\/h2>\n<p>L'essai soutient un signal humain de phase 2 et une discussion dose-r\u00e9ponse. Elle ne r\u00e8gle pas la maintenance \u00e0 long terme, les \u00e9v\u00e9nements ind\u00e9sirables rares, l'efficacit\u00e9 comparative, l'\u00e9quivalence de fabrication ou l'approbation r\u00e9glementaire. Ces questions n\u00e9cessitent des essais ult\u00e9rieurs et des donn\u00e9es sur les produits examin\u00e9es par les r\u00e9gulateurs.<\/p>","protected":false},"excerpt":{"rendered":"<p>Une lecture tra\u00e7able \u00e0 la source de l'essai randomis\u00e9 de phase 2 sur l'ob\u00e9sit\u00e9, y compris les r\u00e9sultats des groupes de dose, les types d'\u00e9v\u00e9nements ind\u00e9sirables et les limites de l'application d'un dossier d'intervention clinique au mat\u00e9riel de recherche.<\/p>","protected":false},"author":0,"featured_media":850,"template":"","class_list":["post-722","case_study","type-case_study","status-publish","has-post-thumbnail","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v28.0 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Retatrutide Phase 2 Trial: 338 Adults, 48 Weeks<\/title>\n<meta name=\"description\" content=\"A source-traceable reading of the randomized Phase 2 obesity trial, including the dose-group results, adverse-event pattern and the limits of applying a clinical intervention record to research material.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nhdbio.com\/fr\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Retatrutide Phase 2 Obesity Trial: 338 Adults Over 48 Weeks\" \/>\n<meta property=\"og:description\" content=\"A source-traceable reading of the randomized Phase 2 obesity trial, including the dose-group results, adverse-event pattern and the limits of applying a clinical intervention record to research material.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nhdbio.com\/fr\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/\" \/>\n<meta property=\"og:site_name\" content=\"NHD\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-01T15:32:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/retatrutide-phase-2-editorial-v2.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1672\" \/>\n\t<meta property=\"og:image:height\" content=\"941\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/webp\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Peptide Raw Materials and Custom Peptide Synthesis\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\\\/\",\"name\":\"Retatrutide Phase 2 Trial: 338 Adults, 48 Weeks\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/retatrutide-phase-2-editorial-v2.webp\",\"datePublished\":\"2026-09-01T15:21:54+00:00\",\"dateModified\":\"2026-09-01T15:32:23+00:00\",\"description\":\"A source-traceable reading of the randomized Phase 2 obesity trial, including the dose-group results, adverse-event pattern and the limits of applying a clinical intervention record to research material.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/retatrutide-phase-2-editorial-v2.webp\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/retatrutide-phase-2-editorial-v2.webp\",\"width\":1672,\"height\":941,\"caption\":\"Editorial research illustration; not a photograph of trial participants or an actual study site.\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"\u6848\u4f8b\",\"item\":\"https:\\\/\\\/nhdbio.com\\\/case-studies\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Retatrutide Phase 2 Obesity Trial: 338 Adults Over 48 Weeks\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#website\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"name\":\"NHD\",\"description\":\"Peptide Raw Materials and Custom Peptide Synthesis\",\"publisher\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nhdbio.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#organization\",\"name\":\"NHD\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"contentUrl\":\"https:\\\/\\\/nhdbio.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png\",\"width\":2172,\"height\":724,\"caption\":\"NHD\"},\"image\":{\"@id\":\"https:\\\/\\\/nhdbio.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Essai Retatrutide de phase 2\u00a0: adultes 338, semaines 48","description":"Une lecture tra\u00e7able \u00e0 la source de l'essai randomis\u00e9 de phase 2 sur l'ob\u00e9sit\u00e9, y compris les r\u00e9sultats des groupes de dose, les types d'\u00e9v\u00e9nements ind\u00e9sirables et les limites de l'application d'un dossier d'intervention clinique au mat\u00e9riel de recherche.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nhdbio.com\/fr\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/","og_locale":"fr_FR","og_type":"article","og_title":"Retatrutide Phase 2 Obesity Trial: 338 Adults Over 48 Weeks","og_description":"A source-traceable reading of the randomized Phase 2 obesity trial, including the dose-group results, adverse-event pattern and the limits of applying a clinical intervention record to research material.","og_url":"https:\/\/nhdbio.com\/fr\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/","og_site_name":"NHD","article_modified_time":"2026-09-01T15:32:23+00:00","og_image":[{"width":1672,"height":941,"url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/retatrutide-phase-2-editorial-v2.webp","type":"image\/webp"}],"twitter_card":"summary_large_image","twitter_description":"Peptide Raw Materials and Custom Peptide Synthesis","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nhdbio.com\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/","url":"https:\/\/nhdbio.com\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/","name":"Essai Retatrutide de phase 2\u00a0: adultes 338, semaines 48","isPartOf":{"@id":"https:\/\/nhdbio.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nhdbio.com\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/#primaryimage"},"image":{"@id":"https:\/\/nhdbio.com\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/#primaryimage"},"thumbnailUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/retatrutide-phase-2-editorial-v2.webp","datePublished":"2026-09-01T15:21:54+00:00","dateModified":"2026-09-01T15:32:23+00:00","description":"Une lecture tra\u00e7able \u00e0 la source de l'essai randomis\u00e9 de phase 2 sur l'ob\u00e9sit\u00e9, y compris les r\u00e9sultats des groupes de dose, les types d'\u00e9v\u00e9nements ind\u00e9sirables et les limites de l'application d'un dossier d'intervention clinique au mat\u00e9riel de recherche.","breadcrumb":{"@id":"https:\/\/nhdbio.com\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nhdbio.com\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/#primaryimage","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/retatrutide-phase-2-editorial-v2.webp","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/retatrutide-phase-2-editorial-v2.webp","width":1672,"height":941,"caption":"Editorial research illustration; not a photograph of trial participants or an actual study site."},{"@type":"BreadcrumbList","@id":"https:\/\/nhdbio.com\/case-studies\/retatrutide-phase-2-obesity-trial-338-adults-48-weeks\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nhdbio.com\/"},{"@type":"ListItem","position":2,"name":"\u6848\u4f8b","item":"https:\/\/nhdbio.com\/case-studies\/"},{"@type":"ListItem","position":3,"name":"Retatrutide Phase 2 Obesity Trial: 338 Adults Over 48 Weeks"}]},{"@type":"WebSite","@id":"https:\/\/nhdbio.com\/#website","url":"https:\/\/nhdbio.com\/","name":"NHD","description":"Mati\u00e8res premi\u00e8res peptidiques et synth\u00e8se sur mesure","publisher":{"@id":"https:\/\/nhdbio.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nhdbio.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/nhdbio.com\/#organization","name":"NHD","url":"https:\/\/nhdbio.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/","url":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","contentUrl":"https:\/\/nhdbio.com\/wp-content\/uploads\/2026\/09\/codex-clipboard-354c928e-4b5b-482d-9261-02023d4c9680.png","width":2172,"height":724,"caption":"NHD"},"image":{"@id":"https:\/\/nhdbio.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/case_study\/722","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/case_study"}],"about":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/types\/case_study"}],"version-history":[{"count":1,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/case_study\/722\/revisions"}],"predecessor-version":[{"id":727,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/case_study\/722\/revisions\/727"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media\/850"}],"wp:attachment":[{"href":"https:\/\/nhdbio.com\/fr\/wp-json\/wp\/v2\/media?parent=722"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}